BioCentury
ARTICLE | Clinical News

Affimed reports Phase Ib/IIa data of AFM13 for cutaneous lymphoma

February 9, 2018 6:44 PM UTC

Affimed N.V. (NASDAQ:AFMD) reported data from three evaluable patients with relapsed or refractory CD30-positive, cutaneous lymphoma in the first dose cohort of a Phase Ib/IIa trial showing that once-weekly 1.5 mg/kg IV AFM13 led to one complete response and one partial response, plus one case of stable disease.

The open-label, U.S. trial's primary endpoints are the percentage of intratumoral nature killer (NK) cells and T cells that infiltrate into tumors, the number of immune cells in tumor and peripheral blood, and level of plasma cytokine production. Secondary endpoints include safety, objective response rate (ORR), duration of response and progression-free survival (PFS). The trial is sponsored by Columbia University Medical Center...